Drug-free remission, functioning and radiographic damage after 4 years of response-driven treatment in patients with recent-onset rheumatoid arthritis.
about
Down-titration and discontinuation strategies of tumor necrosis factor-blocking agents for rheumatoid arthritis in patients with low disease activityBenefit of early treatment in inflammatory polyarthritis patients with anti-cyclic citrullinated peptide antibodies versus those without antibodiesRemission-induction therapies for early rheumatoid arthritis: evidence to date and clinical implicationsSustained biologic-free and drug-free remission in rheumatoid arthritis, where are we now?Use of risk stratification to target therapies in patients with recent onset arthritis; design of a prospective randomized multicenter controlled trialTime to achieve remission determines time to be in remission.Remission in rheumatoid arthritis.Benefits 8 years after a remission induction regime with an infliximab and methotrexate combination in early rheumatoid arthritis.Infliximab: 12 years of experienceUnderstanding emerging treatment paradigms in rheumatoid arthritisEfficacy of conventional synthetic disease-modifying antirheumatic drugs, glucocorticoids and tofacitinib: a systematic literature review informing the 2013 update of the EULAR recommendations for management of rheumatoid arthritis.Changes and sex differences in patient reported outcomes in rheumatoid factor positive RA-results from a community based study.Pretreatment Prediction of Individual Rheumatoid Arthritis Patients' Response to Anti-Cytokine Therapy Using Serum Cytokine/Chemokine/Soluble Receptor Biomarkers.Little Evidence for Usefulness of Biomarkers for Predicting Successful Dose Reduction or Discontinuation of a Biologic Agent in Rheumatoid Arthritis: A Systematic Review.Maintenance of biologic-free remission with naproxen or no treatment in patients with early, active axial spondyloarthritis: results from a 6-month, randomised, open-label follow-up study, INFAST Part 2.Systematic review of tumor necrosis factor inhibitor discontinuation studies in rheumatoid arthritis.Interferon-α induced remission in three patients with eosinophilic granulomatosis and polyangiitis. A case study.IL-22-producing CD4+T cells in the treatment response of rheumatoid arthritis to combination therapy with methotrexate and leflunomide.When to initiate and discontinue biologic treatments for rheumatoid arthritis?Tocilizumab: is there life beyond anti-TNF blockade?Unresolved issues in biologic therapy for rheumatoid arthritis.Structural damage in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: traditional views, novel insights gained from TNF blockade, and concepts for the future.Newest clinical trial results with antitumor necrosis factor and nonantitumor necrosis factor biologics for rheumatoid arthritisWhat is the evidence for the presence of a therapeutic window of opportunity in rheumatoid arthritis? A systematic literature review.Efficacy of biological disease-modifying antirheumatic drugs: a systematic literature review informing the 2013 update of the EULAR recommendations for the management of rheumatoid arthritis.Benefits and risks of low-dose glucocorticoid treatment in the patient with rheumatoid arthritis.Intensive intervention can lead to a treatment holiday from biological DMARDs in patients with rheumatoid arthritis.Combination therapy for early rheumatoid arthritis: a treatment holiday perspective.Review article: moving towards common therapeutic goals in Crohn's disease and rheumatoid arthritis.Drug-free holiday in patients with rheumatoid arthritis: a qualitative study to explore patients' opinion.Changes in hand bone mineral density and the association with the level of disease activity in patients with rheumatoid arthritis: bone mineral density measurements in a multicenter randomized clinical trial.Similar efficacy and safety of initial COBRA-light and COBRA therapy in rheumatoid arthritis: 4-year results from the COBRA-light trial.Prediction of disease relapses by multibiomarker disease activity and autoantibody status in patients with rheumatoid arthritis on tapering DMARD treatment.Guidelines for the drug treatment of rheumatoid arthritis.Large-joint damage in patients with early rheumatoid arthritis and its association with treatment strategy and damage of the small joints.Randomized comparison of etanercept with usual therapy in an Asian population with active rheumatoid arthritis: the APPEAL trial.Sustained beneficial effects of a protocolized treat-to-target strategy in very early rheumatoid arthritis: three-year results of the Dutch Rheumatoid Arthritis Monitoring remission induction cohort.Risk of alanine transferase (ALT) elevation in patients with rheumatoid arthritis treated with methotrexate in a DAS-steered strategy.Clinical pharmacogenetic model to predict response of MTX monotherapy in patients with established rheumatoid arthritis after DMARD failure.Sex, Symptom Severity, and Quality of Life in Rheumatology.
P2860
Q24193435-2ACF5DE0-8ED2-4B0D-AFD3-129E1694DA5FQ24627677-439C528A-3115-45CD-BA4D-612862282DC3Q26738960-99D9E986-8C54-4F34-854C-7F9800148AC6Q26800154-88C76904-5632-4C15-B8E3-94FC9EE1B189Q33470696-FB045D6C-3F4E-445C-94C2-5BB0AFFF56E8Q34027517-1FAAFD05-9EB9-4C0D-BA7D-2AFCB1884049Q34081946-B790DA28-C510-4561-A9A1-74B85CE13E68Q34123712-E73293F0-0465-44E8-BE8E-E795A71BAAB6Q35070446-2BCFD8F8-259E-47E1-BB00-628BCD5ABB05Q35070450-26701A9E-7EE7-4F06-A7CA-37081F721C6AQ35084199-1790187E-EA48-4CB4-A8CA-C7F5B5F96AC1Q35098178-682F3403-9055-4008-AF30-4828F6372220Q35691806-CCF84086-0C74-44F0-B90D-2112AE98353EQ36151778-FF0FCF38-E91A-415F-8B8B-F27BA2265C37Q37465472-E6C28849-1548-4580-BE37-825831E1E34DQ37567461-B9B58AFA-1ABE-4729-95E7-6FF2CBCCDDE8Q37576518-7E71481B-FA2F-44B3-B3C5-860BB8A3B7A5Q37602033-9A19333B-4A75-4AAC-B4C4-ACA7876A71FAQ37831972-71BB6F6F-0FEC-4181-B9BC-EC5A976A7951Q37832771-9D5430D8-D661-49A4-94C6-170C81BCD52FQ37851001-F8030E77-E81A-48D0-B23E-D7BFA569F5D5Q37882064-2513C809-12A8-4532-AA12-10819D2EC4E3Q38091288-8FD2DAE6-BAF8-4102-96D1-8DE39429CDC4Q38097740-2B90CE96-DD56-48EB-9765-5783C5BF3BF9Q38176549-4E88BEA9-A6FE-49F4-9A10-66BE051C0BAFQ38204350-C1A71839-7171-4529-A410-D1CB1FE1E77CQ38267345-698EFEA9-B518-448C-84A9-7DF1092A54FEQ38270917-0A35D0D3-FAE3-41E9-AEA7-F92B1294E92BQ38752119-4E55FCD0-FE54-4E83-83DC-020A2C2324C7Q39212881-12977656-644C-42F9-88BD-BA329364E503Q39998140-E8F3C64E-03DE-45CD-81F6-85A26911B1F2Q40062771-53E15B97-67A9-4A58-9D1E-BC268C2CA2D2Q41026649-10228F6B-3421-44F5-8901-AF3C34727BBDQ43675571-E4FEED62-9EEF-4CCC-82BB-FC6E68F10600Q44864886-99343735-3A78-426E-9287-C1E3BDD9C097Q44955341-F6F9BB7B-1BE7-426D-AE77-DE8E36BA59D4Q45078242-842E762F-64B0-426C-9D23-A9184AA2795DQ46375268-58476AE1-2090-4A8C-89AD-05B5CA9F5611Q47333469-AB02EC98-E0C0-4BDF-A18B-E20917CB6E0AQ47671088-CC6DB9C6-0FEB-4B23-8D56-1C2E13CC4D42
P2860
Drug-free remission, functioning and radiographic damage after 4 years of response-driven treatment in patients with recent-onset rheumatoid arthritis.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh-hant
name
Drug-free remission, functioni ...... nt-onset rheumatoid arthritis.
@en
Drug-free remission, functioni ...... nt-onset rheumatoid arthritis.
@nl
type
label
Drug-free remission, functioni ...... nt-onset rheumatoid arthritis.
@en
Drug-free remission, functioni ...... nt-onset rheumatoid arthritis.
@nl
prefLabel
Drug-free remission, functioni ...... nt-onset rheumatoid arthritis.
@en
Drug-free remission, functioni ...... nt-onset rheumatoid arthritis.
@nl
P2093
P356
P1476
Drug-free remission, functioni ...... nt-onset rheumatoid arthritis.
@en
P2093
A H Zwinderman
B A C Dijkmans
B A M Grillet
C F Allaart
F C Breedveld
H K Ronday
J K de Vries-Bouwstra
M Güler-Yüksel
P A H M van der Lubbe
P J S M Kerstens
P304
P356
10.1136/ARD.2008.092254
P407
P577
2008-07-28T00:00:00Z